Hancock Whitney Corp Reduces Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Hancock Whitney Corp trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 33.7% in the 4th quarter, HoldingsChannel reports. The firm owned 20,379 shares of the medical research company’s stock after selling 10,362 shares during the quarter. Hancock Whitney Corp’s holdings in Edwards Lifesciences were worth $1,509,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences in the 4th quarter worth approximately $26,000. Millstone Evans Group LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $30,000. Roble Belko & Company Inc purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth $46,000. Finally, Catalyst Capital Advisors LLC acquired a new position in Edwards Lifesciences during the fourth quarter valued at $54,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on EW. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Morgan Stanley lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a “hold” rating in a report on Friday. Finally, Truist Financial lowered their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a report on Friday, April 11th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $79.45.

Edwards Lifesciences Trading Up 1.2 %

Shares of EW stock opened at $76.06 on Friday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The firm has a market capitalization of $44.71 billion, a P/E ratio of 10.91, a PEG ratio of 4.82 and a beta of 1.15. The stock’s fifty day moving average is $70.94 and its two-hundred day moving average is $71.07. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. During the same period in the previous year, the business posted $0.66 earnings per share. Research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the transaction, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,853 shares of company stock valued at $5,163,062. 0.34% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.